Tango Therapeutics Inc
Research Tango Therapeutics Inc (TNGX) on Bullrun: market cap USD 3.58B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTNGX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.58B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 45.51M
- Free cash flow-USD 44.36M
Valuation Snapshot
latest market cap is USD 3.58B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 62.38M | -USD 101.60M | -USD 139.93M | n/a | -0.87 | USD 112.28M | USD 33.57M | USD 346.18M |
| FY2024 | USD 42.07M | -USD 130.30M | -USD 132.26M | n/a | -1.19 | USD 69.53M | USD 36.49M | USD 199.52M |
| FY2023 | USD 36.53M | -USD 101.70M | -USD 119.51M | n/a | -1.08 | USD 66.39M | USD 38.92M | USD 253.11M |
| FY2022 | USD 24.86M | -USD 108.18M | -USD 116.77M | n/a | -1.23 | USD 59.97M | USD 629.00K | USD 249.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.58B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.20B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 332.88M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.01B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 639.29M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 958.32M | n/a | n/a | n/a |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tango Therapeutics Inc's market cap?
Tango Therapeutics Inc's market capitalization is USD 3.58B.
What does Tango Therapeutics Inc do?
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.